secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVS HEALTH Corp (CVS)
CIK:        0000064803
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0000064803-23-000024
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

CVS Health reaffirms FY2023 GAAP EPS $6.90-$7.12 and Adj. EPS $8.50-$8.70
-------------------------------------------------------------------------

- Reaffirms full-year 2023 GAAP diluted EPS guidance range of $6.90 to $7.12.
- Reaffirms Adjusted EPS guidance range of $8.50 to $8.70 and cash flow from operations of $12.5B-$13.5B.
- Expects medical costs to remain in line with pricing; slightly >50% of earnings in H2 2023 with Q3 modestly higher than Q4.
- Guidance unchanged from prior announcement; no new financial results reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/64803/000006480323000024/0000064803-23-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/64803/000006480323000024/cvs-20230531.htm
  HTML page:      https://secwatch.observer/filing/0000064803-23-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer